Literature DB >> 8875335

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model.

F Maignen1, P Tilleul, C Billardon, W Y Xu-Van Opstal, D Pélaprat, P P Elena, P Denis, W Rostène.   

Abstract

Wound healing is the main cause of the failure of filtering surgery in glaucoma. We developed a liposomal delivery system of mitoxantrone (MITX), an anthracyclin derivative, to allow a single adjuvant administration and to lessen ocular side-effects of the drug. In order to evaluate the antiproliferative activity of liposomal MITX, an ex vivo model consisting in the culture of subconjunctival tissue explants from rabbits pretreated with subconjunctival injections of free or liposomal MITX was used. We found that both forms of MITX decreased the growth rate as well as the explant proliferation surfaces 15 days or 1 month after a single administration of the drug in vivo. A morphometric analysis of the cells showed that the surface of the fibroblasts exposed to both forms of MITX was from 10 to 12 times as important as that of the control cells exposed to the empty liposomes and to the control buffer. A radioautographic study showed that more than 95% of the fibroblasts exposed to both forms of MITX were in the G1 phase of the cell cycle, while the control cell population was equally distributed among the different phases of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875335     DOI: 10.1089/jop.1996.12.289

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  1 in total

1.  Integrating Differential Gene Expression Analysis with Perturbagen-Response Signatures May Identify Novel Therapies for Thyroid-Associated Orbitopathy.

Authors:  John Y Lee; Ryan A Gallo; Paul J Ledon; Wensi Tao; David T Tse; Daniel Pelaez; Sara T Wester
Journal:  Transl Vis Sci Technol       Date:  2020-08-25       Impact factor: 3.283

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.